RBC Capital analyst Ben Hendrix maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $58.00.

CVS Health stock surged over 11% following a sizable revenue beat and the appointment of new CEO David Joyner. See why I'm ...

Joyner’s comments were his first made publicly since he was promoted less than a month ago to replace Karen S. Lynch, who stepped down. CVS Health has struggled to control costs in its Aetna health ...

CVS Health rated Hold, offers dividend yield, facing challenges from CMS decisions and rising medical costs in healthcare ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

In 2024, retail health care faced significant disruption as industry giants like Walgreens, CVS and Walmart reevaluated their ...

Leverage Ratio: Approximately 4.6 times. CVS Health Corp (NYSE:CVS) achieved a record high retail pharmacy script share of 27.3%, indicating strong market presence. The company introduced Simple ...

CVS Health (NYSE:CVS) just rocked the market with a nearly 11% surge in pre-market trading after its Q3 revenue topped expectations, hitting a staggering $95.4 billion. This beat, the first of ...

We recently compiled a list of the Jim Cramer’s Latest Game Plan: 15 Stocks to Watch. In this article, we are going to take a ...